Common diabetes drugs may carry risk - WOWK 13 Charleston, Huntington WV News, Weather, Sports

Common diabetes drugs may carry risk

Posted: Updated:
  • Most Popular StoriesMost Popular StoriesMore>>

  • Department of Health Alleges Unsafe Practices at McMechen Pain Management Clinic

    Department of Health Alleges Unsafe Practices at McMechen Pain Management Clinic

    Tuesday, July 22 2014 4:20 PM EDT2014-07-22 20:20:59 GMT
    The Ohio Department of Health and the West Virginia Department of Health are encouraging patients of a McMechen pain management clinic to talk with their primary care physician about testing for some infectious diseases following an investigation of the facility by the West Virginia Bureau for Public Health.
    The Ohio Department of Health and the West Virginia Department of Health are encouraging patients of a McMechen pain management clinic to talk with their primary care physician about testing for some infectious diseases following an investigation of the facility by the West Virginia Bureau for Public Health.
  • UPDATE: Man shot during fight on Charleston's east end

    UPDATE: Man shot during fight on Charleston's east end

    Tuesday, July 22 2014 9:10 PM EDT2014-07-23 01:10:50 GMT
    A man was shot in the hand during a robbery on Charleston's east end on July 22 at about 10:30 a.m.
    A man was shot in the hand during a robbery on Charleston's east end on July 22 at about 10:30 a.m.
  • UPDATE: Dirty Girl Mud Run scheduled in Charleston, WV now canceled

    UPDATE: Dirty Girl Mud Run scheduled in Charleston, WV now canceled

    Tuesday, July 22 2014 11:38 PM EDT2014-07-23 03:38:13 GMT
    UPDATE: 13 NEWS has learned the Dirty Girl Mud Run has been officially canceled for this weekend in Charleston. 
    UPDATE: 13 NEWS has learned the Dirty Girl Mud Run has been officially canceled for this weekend in Charleston. 

THURSDAY, Sept. 26 (HealthDay News) -- Diabetes patients who take drugs called sulfonylureas as an initial therapy have a higher risk of death than those who take the diabetes drug metformin, a new study says.

The British researchers said the findings suggest that it may no longer be appropriate to offer sulfonylureas as a first-line treatment.

Diabetes experts in the United States agreed that the study could have an impact on care.

The findings "will change the practice of glucose [blood sugar]-lowering therapy," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City.

But he added that "more study is need to confirm this data," and use of the alternative drug, metformin, is not always the answer. "Metformin and other oral hypoglycemic agents have their drawbacks, and probably we will see earlier use of insulin in type 2 diabetics," Mezitis said.

Both metformin (brand names include Glucophage and Fortamet) and sulfonylureas (glyburide and glipizide) are commonly prescribed as first-line therapies for patients and have been available since the 1950s.

The new study was funded by drugmaker Bristol-Myers Squibb, which makes Glucophage.

Researchers analyzed data from thousands of people in the United Kingdom who were diagnosed with type 2 diabetes and began first-line blood sugar-lowering treatments between 2000 and 2012 and were followed for an average of three years.

Patients who took sulfonylureas only were 58 percent more likely to die from any cause than those who took metformin only, according to the study, which was presented Wednesday at the annual meeting of the European Association for the Study of Diabetes in Barcelona, Spain.

The findings suggest "that treatment with first-line monotherapy [one-drug only] with sulfonylureas should be reconsidered," wrote a team led by Dr. Craig Currie of Cardiff University.

Another U.S. expert said sulfonylureas and metformin fight diabetes in different ways. Sulfonylureas work "by increasing insulin release from the beta cells in the pancreas," while metformin "acts by suppressing glucose production by the liver," explained Dr. Patricia Vuguin, a pediatric endocrinologist at the Cohen Children's Medical Center of New York in New Hyde Park, N.Y.

Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.